Contrasting Vectura Group (OTCMKTS:VEGPF) & ProPhase Labs (NASDAQ:PRPH)

Volatility & Risk

Vectura Group has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.47, meaning that its stock price is 147% less volatile than the S&P 500.

Insider & Institutional Ownership

9.4% of ProPhase Labs shares are held by institutional investors. 20.7% of ProPhase Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Vectura Group and ProPhase Labs’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vectura Group	N/A	N/A	N/A
ProPhase Labs	-217.64%	-62.92%	-30.22%

Valuation and Earnings

This table compares Vectura Group and ProPhase Labs”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vectura Group	$244.76 million	4.37	$157.16 million	$0.26	6.81
ProPhase Labs	$6.77 million	2.03	-$16.78 million	($1.26)	-0.26

Vectura Group has higher revenue and earnings than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than Vectura Group, indicating that it is currently the more affordable of the two stocks.

Summary

Vectura Group beats ProPhase Labs on 9 of the 11 factors compared between the two stocks.

About Vectura Group

Vectura Group Plc engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. The company operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. Vectura Group was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom.

About ProPhase Labs

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.